Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: The two major incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are being actively explored as anti‐diabetic agents because they lower blood glucose through multiple mechanisms. The rapid inactivation of GIP and GLP‐1 by the ubiquitous enzyme, dipeptidyl peptidase IV (DPP IV) makes their biological actions short‐lived, but stable agonists such as N‐acetylated GIP (N‐AcGIP) and exendin(1‐39)amide have been advocated as stable and specific GIP and GLP‐1 analogues. Methods: The present study examined the sub‐chronic (14 days) anti‐diabetic actions of single daily doses of N‐AcGIP and exendin(1‐39)amide given alone or in combination to obese diabetic (ob/ob) mice over a 14‐day period. Results: Initial experiments confirmed the potent anti‐hyperglycaemic and insulinotropic properties of N‐AcGIP and exendin(1‐39)amide. Sub‐chronic administration of N‐AcGIP alone or in combination with exendin(1‐39)amide significantly decreased non‐fasting plasma glucose and improved glucose tolerance compared to control ob/ob mice. This was associated with a significant enhancement of the insulin response to glucose and a notable improvement of insulin sensitivity. Combined treatment with N‐AcGIP and exendin(1‐39)amide also significantly decreased glycated haemoglobin. Exendin(1‐39)amide alone had no significant effect on any of the metabolic parameters monitored. In addition, no significant effects were observed on body weight and food intake in any of the treatment groups. Conclusions: The results illustrate significant anti‐diabetic potential of N‐AcGIP alone and in combination with exendin(1‐39)amide. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Circulation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250 · cited 1×
“GIP and GLP-1 are transcribed on separate genes [7,8] and each possess its own specific G-protein coupled receptor [9].”
BackgroundGreen, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111 · cited 2×
“These anti-diabetic features of GIP and GLP-1 provide the basis for a recent upsurge of interest in the pharmaceutical industry for exploitation as new therapies [4,5].”
BackgroundSelf-citationGreen, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097824 · Cited by 49 · cited 3×
“Some evidence for benefit of combined treatment with exendin(1–39)amide was obtained, but this GLP-1 mimetic is considerably less effective than N-AcGIP or (Val8)GLP-1 [19] in this commonly employed diabetic animal model.”
BackgroundSelf-citation
Cited by
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Laboratory animals as surrogate models of human obesity
Nilsson, C., Raun, K., Yan, F.-F., Larsen, M. O., & Tang-Christensen, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.203 · Cited by 275
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53
Metadata
- Authors
- Irwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2007-02-21
- Volume
- 23
- Issue
- 7
- Pages
- 572-579
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2125364438
- Cited by
- 32
- References
- 8
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide. https://app.cochat.ai/papers/10.1002/dmrr.729
- The paper
- Irwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R. (2007). Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.729
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.